المؤلفون: Oka, Shiro, Tanaka, Shinji, Kajiwara, Yoshiki, Saito, Shoichi, Fukunaga, Yosuke, Takamatsu, Manabu, Kawachi, Hiroshi, Hotta, Kinich, Ikematsu, Hiroaki, Kojima, Motohiro, Saito, Yutaka, Yamada, Masayoshi, Kanemitsu, Yukihide, Sekine, Shigeki, Nagata, Shinji, Yamada, Kazutaka, Kobayashi, Nozomu, Ishihara, Soichiro, Saitoh, Yusuke, Matsuda, Kenji, Togashi, Kazutomo, Komori, Koji, Ishiguro, Megumi, Kuwai, Toshio, Okuyama, Takashi, Ohuchi, Akihiro, Ohnuma, Shinobu, Sakamoto, Kazuhiro, Sugai, Tamotsu, Katsumata, Kenji, Matsushita, Hiro-o, Yamano, Hiro-o, Eda, Hirotsugu, Uraoka, Toshio, Akimoto, Naohiko, Kobayashi, Hirotoshi, Sugihara, Kenichi, Ueno, Hideki

المصدر: American Journal of Gastroenterology ; ISSN 0002-9270 1572-0241

الوصف: INTRODUCTION: To verify the value of the pathological criteria for additional treatment in locally resected pT1 colorectal carcinoma (CRC) which have been used in the Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines since 2009. METHODS: We enrolled 4,719 patients with pT1 CRC treated at 27 institutions between July 2009 and December 2016 (1,259 patients with local resection alone [group A], 1,508 patients with additional surgery after local resection [group B], and 1,952 patients with surgery alone [group C]). All 5 factors of the JSCCR guidelines (submucosal resection margin, tumor histologic grade, submucosal invasion depth, lymphovascular invasion, and tumor budding) for lymph node metastasis (LNM) had been diagnosed prospectively. RESULTS: Any of the risk factors were present in 3,801 patients. The LNM incidence was 10.3% (95% confidence interval 9.3–11.4) in group B/C patients with risk factors, whereas it was 1.8% (95% confidence interval 0.4–5.2) in those without risk factors ( P < 0.01). In group A, the incidence of recurrence was 3.4% in patients with risk factors, but it was only 0.1% in patients without risk factors ( P < 0.01). The disease-free survival rate of group A patients classified as risk positive was significantly worse than those of groups B and C patients. However, the 5-year disease-free survival rate in group A patients with no risk was 99.2%. DISCUSSION: Our large-scale real-world multicenter study demonstrated the validity of the JSCCR criteria for pT1 CRC after local resection, especially regarding favorable outcomes in patients with low risk of LNM.

الإتاحة: https://doi.org/10.14309/ajg.0000000000002715Test

المؤلفون: Kitajima, Kazuhiro, Shiomi, Hideyuki, Kihara, Takako, Hirono, Seiko, Nakano, Ryota, Okamoto, Tomohiro, Yagi, Chisako, Eda, Hirotsugu, Matsuda, Kosuke, Hatano, Michiko, Yoshida, Makoto, Kono, Hiroshi, Hirota, Seiichi, Minami, Tetsuya, Yamakado, Koichiro

المصدر: Case Reports in Oncology ; page 543-549 ; ISSN 1662-6575

مصطلحات موضوعية: Oncology

الوصف: We report a 58-year-old male with a histopathologically proven grade 2 (G2) pancreatic neuroendocrine neoplasm and multiple abdominal node metastases by use of a laparoscopic pancreatic body and tail resection procedure, plus abdominal lymph node dissection. A primary pancreatic tail neuroendocrine tumor sized 20 × 25 mm was detected by contrast-enhanced computed tomography, somatostatin receptor scintigraphy (SRS), and fluorodeoxyglucose positron emission tomography (FDG-PET) examinations and pathologically diagnosed as a pancreatic neuroendocrine tumor (PNET, G2) based on positive immunostaining for somatostatin receptor (SSTR) type 2. Of three metastatic histopathological lymph nodes, two measured 18 × 21 and 10 × 12 mm, respectively, with whole strong SSTR immunostaining showing moderate uptake in SRS findings, whereas the other node, sized 8 × 10 mm, had strong SSTR immunostaining only in a small 6 × 6-mm-sized portion and showed no uptake in SRS findings, likely because of the limited spatial resolution of scintigraphy. On the other hand, only the largest node (18 × 21 mm) was visualized by FDG-PET. SRS may be useful for metastatic lymph node diagnosis based on SSTR immunostaining, though a disadvantage is the spatial resolution limitation.

الإتاحة: https://doi.org/10.1159/000531572Test
https://karger.com/cro/article-pdf/16/1/543/4012164/000531572.pdfTest

المؤلفون: Kajiwara, Yoshiki, Oka, Shiro, Tanaka, Shinji, Nakamura, Takahiro, Saito, Shoichi, Fukunaga, Yosuke, Takamatsu, Manabu, Kawachi, Hiroshi, Hotta, Kinichi, Ikematsu, Hiroaki, Kojima, Motohiro, Saito, Yutaka, Yamada, Masayoshi, Kanemitsu, Yukihide, Sekine, Shigeki, Nagata, Shinji, Yamada, Kazutaka, Kobayashi, Nozomu, Ishihara, Soichiro, Saitoh, Yusuke, Matsuda, Kenji, Togashi, Kazutomo, Komori, Koji, Ishiguro, Megumi, Kuwai, Toshio, Okuyama, Takashi, Ohuchi, Akihiro, Ohnuma, Shinobu, Sakamoto, Kazuhiro, Sugai, Tamotsu, Katsumata, Kenji, Matsushita, Hiro-o, Yamano, Hiro-o, Eda, Hirotsugu, Uraoka, Toshio, Akimoto, Naohiko, Kobayashi, Hirotoshi, Ajioka, Yoichi, Sugihara, Kenichi, Ueno, Hideki

المصدر: Gastrointestinal Endoscopy ; volume 97, issue 6, page 1119-1128.e5 ; ISSN 0016-5107

الإتاحة: https://doi.org/10.1016/j.gie.2023.01.022Test
https://api.elsevier.com/content/article/PII:S0016510723000263?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0016510723000263?httpAccept=text/plainTest

المؤلفون: Yoshimoto, Takanori, Oshima, Tadayuki, Fukada, Takashi, Imamura, Nobuko, Nakanishi, Takashi, Ebisutani, Nobuhiko, Morishita, Daisuke, Mieno, Masatoshi, Nakai, Keisuke, Sei, Hiroo, Kitayama, Yoshitaka, Eda, Hirotsugu, Okugawa, Takuya, Tomita, Toshihiko, Fukui, Hirokazu, Shinzaki, Shinichiro

المصدر: International Journal of Clinical Oncology; Feb2024, Vol. 29 Issue 2, p142-148, 7p

مصطلحات موضوعية: ESOPHAGEAL cancer, FILGRASTIM, NEOADJUVANT chemotherapy, DOCETAXEL, CANCER patients

مستخلص: Background: Neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy is a new standard for locally advanced esophageal squamous cell carcinoma. The optimal timing of pegfilgrastim with the DCF regimen to prevent febrile neutropenia (FN) remains controversial. The effectiveness of concomitant pegfilgrastim administration with continuous 5-fluorouracil (5-FU) infusion in the DCF regimen was therefore assessed. Methods: All patients who received neoadjuvant DCF for esophageal cancer were retrospectively assessed. Patients who had been scheduled to receive pegfilgrastim on days 3–5 (early group) or days 7–9 (regular group) of the DCF regimen were included. Uni- and multivariate analyses were used to assess risk factors for FN. Results: Eighty-eight patients were included in the analysis. The 26 patients in the early group received pegfilgrastim as scheduled. In the 62 patients of the regular group, 51 received pegfilgrastim at a median of 7 days after starting DCF chemotherapy. However, 11 patients in the regular group could not receive pegfilgrastim. Twenty-two patients of the regular group and 2 patients of the early group developed FN after the first session of DCF. Early administration of pegfilgrastim and grade 4 neutropenia were significantly associated with onset of FN, with multivariate analysis identifying early administration of pegfilgrastim as an independent preventive factor and grade 4 neutropenia as a risk factor, after adjusting for sex and age. Conclusion: Early pegfilgrastim administration is a safe approach that reduces the incidence of FN in DCF therapy. Using pegfilgrastim with continuous 5-FU infusion in the DCF regimen represents a reasonable option to prevent FN. [ABSTRACT FROM AUTHOR]

: Copyright of International Journal of Clinical Oncology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Yamada, Takeshi, Kataoka, Kozo, Mori, Keita, Kudo, Toshihiro, Shiozawa, Manabu, Takase, Naoto, Ito, Kazuma, Kimura, Kei, Song, Jihyung, Matsuhashi, Nobuhisa, Miyasaka, Toshimitsu, Tajima, Jesse Yu, Beppu, Naohito, Eda, Hirotsugu, Oi, Yuka, Yamazaki, Kentaro, Ikeda, Masataka

المصدر: Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p193-193, 235p

المؤلفون: Yoshimoto, Takanori, Oshima, Tadayuki, Fukada, Takashi, Imamura, Nobuko, Nakanishi, Takashi, Ebisutani, Nobuhiko, Morishita, Daisuke, Mieno, Masatoshi, Nakai, Keisuke, Sei, Hiroo, Kitayama, Yoshitaka, Eda, Hirotsugu, Okugawa, Takuya, Tomita, Toshihiko, Fukui, Hirokazu, Shinzaki, Shinichiro

المصدر: International Journal of Clinical Oncology ; volume 29, issue 2, page 142-148 ; ISSN 1341-9625 1437-7772

مصطلحات موضوعية: Oncology, Hematology, General Medicine, Surgery

الإتاحة: https://doi.org/10.1007/s10147-023-02438-3Test

المؤلفون: Nishii, Norio, Oshima, Tadayuki, Li, Min, Eda, Hirotsugu, Nakamura, Kumiko, Tamura, Akio, Ogawa, Tomohiro, Yamasaki, Takahisa, Kondo, Takashi, Kono, Tomoaki, Tozawa, Katsuyuki, Tomita, Toshihiko, Fukui, Hirokazu, Miwa, Hiroto

المصدر: Pharmacology ; volume 105, issue 1-2, page 102-108 ; ISSN 0031-7012 1423-0313

الوصف: Introduction: Lubiprostone, a chloride channel activator, is said to reduce epithelial permeability. However, whether lubiprostone has a direct effect on the epithelial barrier function and how it modulates the intestinal barrier function remain unknown. Therefore, the effects of lubiprostone on intestinal barrier function were evaluated in vitro. Methods: Caco-2 cells were used to assess the intestinal barrier function. To examine the expression of claudins, immunoblotting was performed with specific antibodies. The effects of lubiprostone on cytokines (IFNγ, IL-6, and IL-1β) and aspirin-induced epithelial barrier disruption were assessed by transepithelial electrical resistance (TEER) and fluorescein isothiocyanate (FITC) labeled-dextran permeability. Results: IFNγ, IL-6, IL-1β, and aspirin significantly decreased TEER and increased epithelial permeability. Lubiprostone significantly improved the IFNγ-induced decrease in TEER in a dose-dependent manner. Lubiprostone significantly reduced the IFNγ-induced increase in FITC labeled-dextran permeability. The changes induced by IL-6, IL-1β, and aspirin were not affected by lubiprostone. The expression of claudin-1, but not claudin-3, claudin-4, occludin, and ZO-1 was significantly increased by lubiprostone. Conclusion: Lubiprostone significantly improved the IFNγ-induced decrease in TEER and increase in FITC labeled-dextran permeability. Lubiprostone increased the expression of claudin-1, and this increase may be related to the effect of lubiprostone on the epithelial barrier function.

الإتاحة: https://doi.org/10.1159/000503054Test
https://www.karger.com/Article/Pdf/503054Test

المؤلفون: Li, Min, Oshima, Tadayuki, Nishii, Norio, Horikawa, Tomoki, Michigami, Yuki, Kitayama, Yoshitaka, Eda, Hirotsugu, Nakamura, Kumiko, Tamura, Akio, Ogawa, Tomohiro, Yamasaki, Takahisa, Okugawa, Takuya, Kondo, Takashi, Kono, Tomoaki, Tozawa, Katsuyuki, Tomita, Toshihiko, Fukui, Hirokazu, Watari, Jiro, Miwa, Hiroto

المصدر: Gastroenterology ; volume 156, issue 6, page S-731 ; ISSN 0016-5085

مصطلحات موضوعية: Gastroenterology, Hepatology

الإتاحة: https://doi.org/10.1016/s0016-5085Test(19)38760-8
https://api.elsevier.com/content/article/PII:S0016508519387608?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0016508519387608?httpAccept=text/plainTest

المؤلفون: Tomita, Toshihiko, Kitayama, Yoshitaka, Eda, Hirotsugu, Nakamura, Kumiko, Tamura, Akio, Ogawa, Tomohiro, Yamasaki, Takahisa, Okugawa, Takuya, Kondo, Takashi, Kono, Tomoaki, Tozawa, Katsuyuki, Oshima, Tadayuki, Fukui, Hirokazu, Watari, Jiro, Miwa, Hiroto

المصدر: Gastroenterology ; volume 156, issue 6, page S-310 ; ISSN 0016-5085

مصطلحات موضوعية: Gastroenterology, Hepatology

الإتاحة: https://doi.org/10.1016/s0016-5085Test(19)37595-x
https://api.elsevier.com/content/article/PII:S001650851937595X?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S001650851937595X?httpAccept=text/plainTest

المؤلفون: Tomita, Toshihiko, Fukui, Hirokazu, Okugawa, Takuya, Nakanishi, Takashi, Mieno, Masatoshi, Nakai, Keisuke, Eda, Hirotsugu, Kitayama, Yoshitaka, Oshima, Tadayuki, Shinzaki, Shinichiro, Miwa, Hiroto

المصدر: Journal of Clinical Medicine; May2023, Vol. 12 Issue 10, p3368, 12p

مصطلحات موضوعية: IRRITABLE colon, CROHN'S disease, BIFIDOBACTERIUM bifidum, GUT microbiome, INTESTINES, LONGITUDINAL method

مستخلص: Diarrhea-predominant irritable bowel syndrome (IBS-D)-like symptoms are distressing for patients with quiescent Crohn's disease (qCD) and worsen their quality of life. In the present study, we assessed the effect of the probiotic Bifidobacterium bifidum G9-1 (BBG9-1) on the intestinal environment and clinical features in patients with qCD. Eleven patients with qCD, who met the Rome III diagnostic criteria for IBS-D, received BBG9-1 (24 mg) orally three times daily for 4 weeks. Indices of the intestinal environment (fecal calprotectin level and gut microbiome) and clinical features (CD/IBS-related symptoms, quality of life and stool irregularities) were evaluated before and after treatment. Treatment with BBG9-1 tended to reduce the IBS severity index in the studied patients (p = 0.07). Among gastrointestinal symptoms, abdominal pain and dyspepsia tended to be improved by the BBG9-1 treatment (p = 0.07 and p = 0.07, respectively), and IBD-related QOL showed a significant improvement (p = 0.007). With regard to mental status, the patient anxiety score was significantly lower at the endpoint of BBG9-1 treatment than at the baseline (p = 0.03). Although BBG9-1 treatment did not affect the fecal calprotectin level, it suppressed the serum MCP-1 level significantly and increased the abundance of intestinal Bacteroides in the study patients. The probiotic BBG9-1 is able to improve IBD-related QOL with a reduction of anxiety score in patients with quiescent CD and IBS-D-like symptoms. [ABSTRACT FROM AUTHOR]

: Copyright of Journal of Clinical Medicine is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)